Skip to content
Study details
Enrolling now

Autologous Stem Cell Transplant for Autoimmune Diseases

Stephan Grupp MD PhD
NCT IDNCT05029336ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

20

Study length

about 5.2 years

Ages

8–25

Locations

1 site in PA

What this study is about

This trial is testing a treatment called autologous stem cell transplant (ASCT) in children and young adults with autoimmune diseases like systemic lupus erythematosus (SLE) or systemic sclerosis (SSc). The goal is to see if ASCT can help remove the harmful, self-attacking immune system in these patients.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Depletion of CD3/CD19 in an autologous stem cell transplant

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Two-year progression free survival

Secondary: Change in quality of life, Event free survival (EFS), Overall survival (OS)

Body systems

Immune